Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …

There are significant disparities with regards to incidence, timely diagnosis, access to
treatment, clinical trial participation and health care utilization that negatively impact …

Importance Although racial and ethnic minority patients with sepsis and acute respiratory
failure (ARF) experience worse outcomes, how patient presentation characteristics …

Background: Multiple myeloma (MM) accounts for 10% of hematologic cancers in the US;
however, incidence and mortality occur disproportionately between racial groups in real …

Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain
US Food and Drug Administration approval for patients with relapsed/refractory multiple …

This retrospective observational study evaluated racial disparities among Black and White
patients with multiple myeloma (MM). We included patients from a longitudinal de-identified …

Autologous hematopoietic stem cell transplantation (ASCT) is the standard of care for
eligible patients with multiple myeloma (MM) to prolong progression-free survival (PFS) …

Several landmark therapeutic advances in multiple myeloma (MM) have led to an
unprecedented number of options available to patients and their physicians as shared …

Multiple myeloma (MM) is the second most common hematologic malignancy in the US [1].
Despite therapeutic advances and overall improved survival, large racial and ethnic …

Simple Summary There is a growing need to clarify the effect of modifiable lifestyle factors
such as obesity on outcomes of multiple myeloma (MM). In this paper, we examined the …